



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

21 June 2017  
EMA/CHMP/ICH/379801/2009  
Committee for Human Medicinal Products

## ICH guideline Q4B Annex 9 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on tablet friability - general chapter Step 5

Transmission to CHMP	June 2009
Transmission to interested parties	June 2009
Deadline for comments	September 2009
Final approval by CHMP	November 2009
Date for coming into operation	May 2010



# ICH guideline Q4B Annex 9 on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on tablet friability - general chapter

## Table of contents

<b>1. Introduction .....</b>	<b>3</b>
<b>2. Q4B outcome .....</b>	<b>3</b>
2.1. Analytical procedures.....	3
2.2. Acceptance criteria .....	3
<b>3. Timing of annex implementation .....</b>	<b>3</b>
<b>4. Considerations for implementation.....</b>	<b>3</b>
4.1. General consideration .....	3
4.2. FDA consideration .....	3
4.3. EU consideration .....	3
4.4. MHLW consideration .....	4
4.5. Health Canada consideration.....	4
<b>5. References used for the Q4B evaluation .....</b>	<b>4</b>

# 1. Introduction

This annex is the result of the Q4B process for the Tablet Friability General Chapter.

The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).

## 2. Q4B outcome

### 2.1. Analytical procedures

The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the analytical procedures described in the official pharmacopoeial texts, Ph.Eur. 2.9.7. Friability of Uncoated Tablets, JP General Information 26. Tablet Friability Test, and USP <1216> Tablet Friability, can be used as interchangeable in the ICH regions.

### 2.2. Acceptance criteria

For interchangeability, the loss of mass for a single determination should be not more than 1.0 percent, unless otherwise specified in the dossier. When three determinations are conducted, then the mean loss of mass for the three determinations should be not more than 1.0 percent, unless otherwise specified in the dossier.

## 3. Timing of annex implementation

When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region. Timing might differ for each region.

## 4. Considerations for implementation

### 4.1. General consideration

When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in Section 2.1 of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes.

### 4.2. FDA consideration

Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in Section 2.1 of this annex can be considered interchangeable. However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.

### 4.3. EU consideration

For the European Union, regulatory authorities can accept the reference in a marketing authorisation application, renewal or variation application citing the use of the corresponding text from another pharmacopoeia as referenced in Section 2.1, in accordance with the conditions set out in this annex, as fulfilling the requirements for compliance with the Ph. Eur. Chapter 2.9.7. on the basis of the declaration of interchangeability made above.

#### **4.4. MHLW consideration**

The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.

#### **4.5. Health Canada consideration**

In Canada any of the pharmacopoeial texts cited in Section 2.1 of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable.

### **5. References used for the Q4B evaluation**

5.1 The PDG Stage 5B sign-off document:

Japanese Pharmacopoeial Forum, Volume 14, number 1 (March 2005).

5.2 The pharmacopoeial references for Residue on Ignition/Sulphated Ash for this annex are:

5.2.1 European Pharmacopoeia (Ph. Eur.): Supplement 6.6 (published June 2009, official January 2010), Friability of Uncoated Tablets (reference 01/2010:20907).

5.2.2 Japanese Pharmacopoeia (JP): The JP General Information 26. Tablet Friability Test as it appears in the JP Fifteenth Edition (March 31, 2006, The Ministry of Health, Labour and Welfare Ministerial Notification No. 285), officially updated by errata published by MHLW at [http://www.std.pmda.go.jp/jpPUB/Data/ENG/jpdata/H201105\\_jp15\\_errata.pdf](http://www.std.pmda.go.jp/jpPUB/Data/ENG/jpdata/H201105_jp15_errata.pdf) on November 5, 2008.

5.2.3 United States Pharmacopoeia (USP): <1216> Tablet Friability, official in USP 32, May 1, 2009.